Skye Bioscience, Inc.

NasdaqGM:SKYE Stock Report

Market Cap: US$30.3m

Skye Bioscience Management

Management criteria checks 1/4

Skye Bioscience's CEO is Punit Dhillon, appointed in Aug 2020, has a tenure of 5.75 years. total yearly compensation is $1.36M, comprised of 44.8% salary and 55.2% bonuses, including company stock and options. directly owns 0.48% of the company’s shares, worth $146.93K. The average tenure of the management team and the board of directors is 1.7 years and 1.8 years respectively.

Key information

Punit Dhillon

Chief executive officer

US$1.4m

Total compensation

CEO salary percentage44.79%
CEO tenure5.8yrs
CEO ownership0.5%
Management average tenure1.7yrs
Board average tenure1.8yrs

Recent management updates

Recent updates

Analysis Article • Feb 04

Here's Why Skye Bioscience (NASDAQ:SKYE) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Oct 01

Skye Bioscience: Promising Nimacimab Data Supports Buy Rating

Summary Skye Bioscience is rated Buy, driven by nimacimab’s strong safety, durable weight-loss profile, and upcoming Phase 2a results. SKYE’s nimacimab targets the expanding anti-obesity market, showing potential as monotherapy, combination, or maintenance therapy, with favorable early data. Risks include clinical trial uncertainties, manufacturing reliance, and regulatory scrutiny, but SKYE’s cash runway extends through Q1 2027, supporting key milestones. SKYE trades at a conservative P/B ratio slightly above the industry average, offering potential upside without excessive premium risk in a competitive sector. Read the full article on Seeking Alpha
Analysis Article • Sep 06

Is Skye Bioscience (NASDAQ:SKYE) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Apr 22

Will Skye Bioscience (NASDAQ:SKYE) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Apr 16

A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value

Summary Weight loss drug stocks like Novo Nordisk have dropped significantly lately. This presents potential value opportunities in a market projected to grow to $105 billion by 2035. Skye Bioscience's nimacimab, in Phase 2a trials, shows promise with significant weight loss results in mouse models, making it a speculative but potentially rewarding investment. 26-week results for the Phase 2a are expected in late Q3 or early Q4, so positive catalysts are on the horizon. SKYE currently trades essentially at cash value, meaning investors who buy in today get a weight loss drug candidate essentially for free. Read the full article on Seeking Alpha
Seeking Alpha • Dec 10

Skye Bioscience: Nimacimab Targets Safer Weight Loss, Speculative Buy

Summary Skye Bioscience's Nimacimab shows promising Phase 1 safety data and is in Phase 2 trials, potentially revolutionizing obesity treatment with minimal neuropsychiatric side effects. Nimacimab’s large-molecule design avoids neuropsychiatric side effects, a major issue with earlier CB1 inhibitors like rimonabant and monlunabant. The drug’s preclinical evidence suggests fat-specific weight loss, lean muscle preservation, and appetite regulation, positioning it as a competitive alternative to GLP-1 therapies. SKYE seems undervalued, with a market cap of $67.4 million, a P/B ratio of 1.5, and a cash runway of 2.5 years, suggesting significant upside potential. Despite risks related to early-stage IP and low trading volume, SKYE's promising IP and near-term catalysts justify a speculative "Buy" rating. Read the full article on Seeking Alpha
Seeking Alpha • Sep 04

Skye: Moving Weight Loss Drugs To The Next Level

Summary Skye Bioscience, Inc. interim data from phase 2 CBbeyondTM study, using nimacimab for the treatment of patients with obesity, is expected Q2 and Q4 of 2025. Experimental arm added into phase 2 CBeyondTM study, which is combining the use of nimacimab with Wegovy for the treatment of patients with obesity. The global obesity drugs market is expected to reach $105 billion in 2030. Several factors differentiate CB1 inhibitor nimacimab compared to other weight loss drugs, such as: Potential for less frequent dosing, less gastrointestinal side effects and long-term dosing for patient compliance. Read the full article on Seeking Alpha
Analysis Article • Aug 11

Is Skye Bioscience (NASDAQ:SKYE) Using Debt In A Risky Way?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

CEO Compensation Analysis

How has Punit Dhillon's remuneration changed compared to Skye Bioscience's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025US$1mUS$610k

-US$56m

Sep 30 2025n/an/a

-US$51m

Jun 30 2025n/an/a

-US$42m

Mar 31 2025n/an/a

-US$33m

Dec 31 2024US$6mUS$458k

-US$27m

Sep 30 2024n/an/a

-US$21m

Jun 30 2024n/an/a

-US$42m

Mar 31 2024n/an/a

-US$37m

Dec 31 2023US$2mUS$450k

-US$38m

Sep 30 2023n/an/a

-US$43m

Jun 30 2023n/an/a

-US$21m

Mar 31 2023n/an/a

-US$22m

Dec 31 2022US$668kUS$433k

-US$19m

Sep 30 2022n/an/a

-US$12m

Jun 30 2022n/an/a

-US$11m

Mar 31 2022n/an/a

-US$9m

Dec 31 2021US$900kUS$400k

-US$9m

Sep 30 2021n/an/a

-US$8m

Jun 30 2021n/an/a

-US$7m

Mar 31 2021n/an/a

-US$6m

Dec 31 2020US$615kUS$160k

-US$7m

Sep 30 2020n/an/a

-US$207k

Jun 30 2020n/an/a

-US$4m

Mar 31 2020n/an/a

US$13m

Dec 31 2019US$65kn/a

US$1m

Compensation vs Market: Punit's total compensation ($USD1.36M) is above average for companies of similar size in the US market ($USD622.91K).

Compensation vs Earnings: Punit's compensation has been consistent with company performance over the past year.

CEO

Punit Dhillon (45 yo)

5.8yrs
Tenure
US$1,361,831
Compensation

Mr. Punit S. Dhillon, BA, has been Chief Executive Officer of Skye Bioscience, Inc. since August 10, 2020 and served as its Principal Accounting Officer since February 20, 2026 until March 31, 2026. Mr. Dh...

Leadership Team

NamePositionTenureCompensationOwnership
Punit Dhillon
President5.8yrsUS$1.36m0.48%
$ 146.9k
Tu Diep
Chief Operating Officer1.3yrsUS$875.94k0.11%
$ 33.7k
John Sharp
CFO and Principal Financial & Accounting Officerless than a yearno datano data
Christopher Twitty
Chief Scientific Officer3.4yrsno data0.23%
$ 70.1k
Puneet Arora
Chief Medical Officer1.7yrsno datano data
1.7yrs
Average Tenure
53yo
Average Age

Experienced Management: SKYE's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Punit Dhillon
President8.3yrsUS$1.36m0.48%
$ 146.9k
Paul Grayson
Independent Chairman of the Board2.8yrsUS$369.36k0.28%
$ 84.7k
Andrew Schwab
Director2.8yrsUS$109.44k0%
$ 0
Louis Aronne
Member of Clinical & Scientific Advisory Board1.8yrsno datano data
Lee Kaplan
Member of Clinical & Scientific Advisory Board1.8yrsno datano data
Annalisa Lisa Jenkins
Independent Director2.3yrsUS$133.82k0%
$ 0
Karen Smith
Independent Director1.8yrsUS$131.94k0%
$ 0
Deborah Charych
Independent Director3.3yrsUS$116.94k0%
$ 0
Rekha Kumar
Member of Clinical & Scientific Advisory Board1.8yrsno datano data
Beverly Tchang
Member of Clinical & Scientific Advisory Board1.8yrsno datano data
Marcus Goncalves
Member of Clinical & Scientific Advisory Board1.8yrsno datano data
1.8yrs
Average Tenure
60yo
Average Age

Experienced Board: SKYE's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/11 01:05
End of Day Share Price 2026/05/11 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Skye Bioscience, Inc. is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristen KluskaCantor Fitzgerald & Co.
Jonathan WollebenCitizens JMP Securities, LLC
Gum-Ming LoweCraig-Hallum Capital Group LLC